Publications by authors named "Koizumi Hideki"
Central serous chorioretinopathy and the sclera: what we have learned so far.
Jpn J Ophthalmol
September 2024
Article Synopsis
- * Recent studies have shown that eyes with CSC have greater choroidal thickness due to dilated large choroidal vessels, indicating that impairments in choroidal circulation play a crucial role in the condition's development.
- * The review suggests a potential connection between thicker sclera in CSC patients and choroidal circulatory disturbances, indicating that further research is needed to fully understand these pathophysiological features.
Article Synopsis
- The study aimed to explore the link between stopping treatment and the development or worsening of diabetic retinopathy (DR) in Japanese type 2 diabetes patients.
- Data was collected from two hospitals, tracking 417 patients over a median of 7 years, comparing those who stopped treatment for at least 12 months with those who continued.
- Results showed a 13% treatment cessation rate, which significantly increased the risk of developing DR, indicating that ceasing treatment is a major risk factor for this condition.
The pachychoroid disease spectrum is a phenotype characterized by alterations in choroidal vasculature which result in outer retinal and choriocapillaris damage and visual loss. The presence of pachyvessels is one of the key features of the pachychoroid phenotype. Recent imaging studies suggest that pachyvessels may form because of choroidal venous congestion in one or more quadrants.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess changes in scleral thickness in patients with Vogt-Koyanagi-Harada (VKH) disease during treatment.
- It involved 34 eyes from 17 patients, measuring scleral thickness at various time points before and after starting corticosteroid treatment.
- Results showed that scleral thickness decreased significantly in eyes with ciliochoroidal effusion within a week of treatment, indicating inflammation impacts both the choroid and sclera in VKH disease.
Purpose: To evaluate the changes in choroidal thickness 1 year after half-dose photodynamic therapy (PDT) for central serous chorioretinopathy (CSC) using widefield swept-source optical coherence tomography.
Methods: We retrospectively reviewed 21 patients with CSC who unilaterally underwent half-dose PDT and completed a 12-month follow-up. Choroidal thickness was evaluated before and after PDT within an 18-mm circular grid centered on the fovea subdivided into nine areas in the treated and untreated fellow eyes.
Purpose: To elucidate the clinical characteristics and progression rates of pachychoroid and conventional geographic atrophy (GA).
Design: Retrospective, multicenter, observational study.
Participants: A total of 173 eyes from 173 patients (38 eyes with pachychoroid GA and 135 with conventional GA) from 6 university hospitals in Japan were included.
This multicentre retrospective study evaluated the 1-year outcomes and safety profile of faricimab in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). Fifty-five patients (57 eyes) underwent loading therapy comprising three monthly faricimab injections. If dryness was achieved by the third month, subsequent treat-and-extend (TAE) follow-up continued at a minimum 8-week interval thereafter.
View Article and Find Full Text PDFPurpose: To evaluate 2-year efficacy, durability, and safety of faricimab in the TENAYA Japan subgroup and pooled global TENAYA/LUCERNE cohort of patients with neovascular age-related macular degeneration (nAMD).
Methods: Subgroup analysis of TENAYA/LUCERNE (NCT03823287/NCT03823300): phase III, multicentre, randomised, active comparator-controlled, double-masked, non-inferiority trials. Treatment-naïve patients aged ≥ 50 years with nAMD were randomised (1:1) to intravitreal faricimab (6.
Central serous chorioretinopathy (CSC) is a relatively common disease that causes vision loss due to macular subretinal fluid leakage and it is often associated with reduced vision-related quality of life. In CSC, the leakage of subretinal fluid through defects in the retinal pigment epithelial layer's outer blood-retina barrier appears to occur secondary to choroidal abnormalities and dysfunction. The treatment of CSC is currently the subject of controversy, although recent data obtained from several large randomized controlled trials provide a wealth of new information that can be used to establish a treatment algorithm.
View Article and Find Full Text PDFPurpose: To evaluate the association between scleral thickness and a newly developed multimodal imaging-based classification of central serous chorioretinopathy (CSC).
Design: Retrospective, cross-sectional study.
Methods: This study included 217 eyes of 217 patients classified as simple or complex CSC based on the established protocols.
Purpose: To investigate the incidence of intraocular inflammation (IOI) and its risk factors following intravitreal injections of brolucizumab for neovascular age-related macular degeneration in Japan.
Methods: A total of 1,351 Japanese consecutive patients with neovascular age-related macular degeneration who were treated with brolucizumab from May 2020 to May 2022 at 14 institutions were examined. The variables analyzed were the number of brolucizumab injections, time to onset of IOI, and risk factors.
Vogt-Koyanagi-Harada disease in a patient with extreme anisometropia.
Am J Ophthalmol Case Rep
December 2023
Purpose: To report Vogt-Koyanagi-Harada (VKH) disease in a patient with extreme anisometropia.
Observations: A 56-year-old woman was referred to our hospital. Her past medical history was significant for amblyopia in the right eye.
Purpose: To assess 6-month outcomes of switching from aflibercept to faricimab in eyes with refractory neovascular age-related macular degeneration (nAMD) previously requiring monthly injections.
Methods: This multicenter retrospective study examined nAMD eyes receiving monthly aflibercept injections switched to faricimab administered monthly up to 4 injections followed by injections at a minimum of 2-month intervals as per drug labeling. Data regarding age, sex, number of previous injections, treatment intervals, and best-corrected visual acuity (BCVA) were collected.
Article Synopsis
- The study aimed to analyze the characteristics and progression of geographic atrophy (GA) linked to age-related macular degeneration (AMD) in a group of 173 Japanese patients aged 50 and older.
- Using fundus autofluorescence images, the research measured the GA area and found a mean progression rate of 1.01 mm per year, with larger baseline GA areas and the presence of reticular pseudodrusen being significant factors in faster progression.
- Findings suggest that clinical features of GA may vary between Asian and other populations, potentially impacting treatment and management strategies.
Article Synopsis
- * Researchers analyzed data from 115 patients, measuring various eye parameters using advanced imaging techniques, but found no significant differences in scleral thickness or other eye measurements between the affected and unaffected eyes.
- * The only notable difference was in the subfoveal choroidal thickness, which was thicker in the affected eyes, suggesting that choroidal thickening might contribute to CSC development, while scleral thickness remains unchanged.
This multicenter study aimed to assess the short-term effectiveness and safety of faricimab in treatment-naïve patients with wet age-related macular degeneration (wAMD) in Japan. We retrospectively reviewed 63 eyes of 61 patients with wAMD, including types 1, 2, and 3 macular neovascularization as well as polypoidal choroidal vasculopathy (PCV). Patients received three consecutive monthly intravitreal injections of faricimab as loading therapy.
View Article and Find Full Text PDFPurpose: To evaluate the 1-year efficacy, durability, and safety of faricimab versus aflibercept in patients with neovascular age-related macular degeneration (nAMD) enrolled in the Japan subgroup of the TENAYA trial.
Study Design: TENAYA (NCT03823287) was a global, phase 3, multicenter, randomized, active comparator-controlled, double-masked, noninferiority, parallel-group, 112-week trial. After completion of global enrollment, additional patients were enrolled in the Japan extension of TENAYA.
Purpose: Central serous chorioretinopathy (CSC) is a retinal disorder characterized by serous retinal detachment with or without pigment epithelial detachment in the posterior pole of the eye. We aimed to elucidate the relationship between scleral thickness and choroidal structure in CSC eyes.
Methods: This single-center retrospective study included 111 eyes of 111 CSC patients.
Purpose: To evaluate and compare the scleral thickness of patients with idiopathic central serous chorioretinopathy (iCSC) and steroid-induced central serous chorioretinopathy (sCSC) using anterior-segment OCT.
Design: Retrospective, comparative study.
Participants: One hundred ten eyes of 110 patients with central serous chorioretinopathy.
Purpose: To investigate the clinical and morphologic factors related to asymmetric dilated vortex veins in central serous chorioretinopathy (CSC).
Design: Retrospective, comparative study.
Participants: One hundred fifty-eight eyes of 158 patients with CSC.
Previous clinical studies have suggested that pachychoroid can induce macular neovascularization (MNV) to develop pachychoroid neovasculopathy (PNV) and that PNV can progress to polypoidal choroidal vasculopathy (PCV). Recent studies based on the pachychoroid concept are now gradually revealing the true nature of, at least some part of, PCV. However, previous studies on PNV and/or PCV have used different frameworks for the classification of PNV, PCV, and neovascular age-related macular degeneration (nAMD).
View Article and Find Full Text PDFPurpose: To investigate short-term treatment outcomes of intravitreal brolucizumab (IVBr) for treatment-naïve neovascular age-related macular degeneration (AMD) in a Japanese multicenter study.
Study Design: Retrospective case control study METHODS: The subjects were 58 eyes of 57 patients with neovascular AMD (43 men and 14 women, mean age 74.6 years) of whom 43 eyes of 42 patients completed initial loading of 3 monthly IVBr injections and were followed for more than 3 months.